IL151371A0 - Modified porcine factor viii and pharmaceutical compositions containing the same - Google Patents

Modified porcine factor viii and pharmaceutical compositions containing the same

Info

Publication number
IL151371A0
IL151371A0 IL15137101A IL15137101A IL151371A0 IL 151371 A0 IL151371 A0 IL 151371A0 IL 15137101 A IL15137101 A IL 15137101A IL 15137101 A IL15137101 A IL 15137101A IL 151371 A0 IL151371 A0 IL 151371A0
Authority
IL
Israel
Prior art keywords
factor viii
same
pharmaceutical compositions
compositions containing
porcine factor
Prior art date
Application number
IL15137101A
Other languages
English (en)
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of IL151371A0 publication Critical patent/IL151371A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Steroid Compounds (AREA)
IL15137101A 2000-03-10 2001-02-16 Modified porcine factor viii and pharmaceutical compositions containing the same IL151371A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (1)

Publication Number Publication Date
IL151371A0 true IL151371A0 (en) 2003-04-10

Family

ID=24085870

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15137101A IL151371A0 (en) 2000-03-10 2001-02-16 Modified porcine factor viii and pharmaceutical compositions containing the same
IL151371A IL151371A (en) 2000-03-10 2002-08-21 Modified porcine factor viii and pharmaceutical compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151371A IL151371A (en) 2000-03-10 2002-08-21 Modified porcine factor viii and pharmaceutical compositions containing the same

Country Status (36)

Country Link
US (3) US6458563B1 (ko)
EP (1) EP1280540B1 (ko)
JP (1) JP4044337B2 (ko)
KR (1) KR100485525B1 (ko)
CN (1) CN1191360C (ko)
AT (1) ATE391512T1 (ko)
AU (2) AU2001238416B2 (ko)
BE (1) BE2016C024I2 (ko)
BR (2) BRPI0109131B8 (ko)
CA (1) CA2400295C (ko)
CY (2) CY1108179T1 (ko)
CZ (1) CZ298250B6 (ko)
DE (1) DE60133541T2 (ko)
DK (1) DK1280540T3 (ko)
EE (1) EE05075B1 (ko)
ES (1) ES2304379T3 (ko)
FR (1) FR16C0016I2 (ko)
HK (1) HK1051004A1 (ko)
HU (2) HU227804B1 (ko)
IL (2) IL151371A0 (ko)
LT (1) LTC1280540I2 (ko)
LU (1) LU93049I2 (ko)
ME (1) MEP8209A (ko)
MX (1) MXPA02008798A (ko)
NL (1) NL300808I2 (ko)
NO (2) NO331935B1 (ko)
NZ (1) NZ520799A (ko)
PL (1) PL202936B1 (ko)
PT (1) PT1280540E (ko)
RS (1) RS50364B (ko)
RU (1) RU2285724C2 (ko)
SI (1) SI1280540T1 (ko)
SK (1) SK286205B6 (ko)
UA (1) UA75064C2 (ko)
WO (1) WO2001068109A1 (ko)
ZA (1) ZA200206810B (ko)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
EP1351986A2 (en) * 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP1572889B1 (en) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EP1456235A4 (en) * 2001-11-30 2005-08-17 Univ Emory VARIANTS OF DOMAIN C2 OF FACTOR VIII
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1636261B1 (en) * 2003-06-26 2007-08-01 MERCK PATENT GmbH Thrombopoietin proteins with improved properties
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
ES2449044T3 (es) * 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
LT3130601T (lt) * 2004-11-12 2020-09-10 Bayer Healthcare Llc Į vietą nukreipta fviii modifikacija
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101379077A (zh) 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2007885B1 (en) * 2006-04-11 2010-07-21 CSL Behring GmbH Method of increasing the in vivo recovery of therapeutic polypeptides
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
US8183345B2 (en) * 2007-11-01 2012-05-22 University Of Rochester Recombinant factor VIII having reduced inactivation by activated protein C
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
ME02979B (me) 2009-06-09 2018-10-20 Prolong Pharmaceuticals Llc Kompozicije hemoglobina
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
EP2742949A1 (en) * 2009-11-13 2014-06-18 Puget Sound Blood Center Factor VIII B cell epitope variants having reduced immunogenicity
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
MY165089A (en) 2010-11-05 2018-02-28 Baxalta Inc A new variant of antihemophilic factor viii having increased specific activity
EA201370151A1 (ru) * 2011-01-05 2013-11-29 Экспрешен Терапетикс, Ллс Высокопродуктивная суспензионная клеточная линия, система и способ ее получения
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
EA029045B1 (ru) 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
KR102212098B1 (ko) 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
SG11201404885RA (en) 2012-02-15 2014-09-26 Amunix Operating Inc Factor viii compositions and methods of making and using same
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
SG11201500045RA (en) 2012-07-11 2015-02-27 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
WO2014089541A2 (en) 2012-12-07 2014-06-12 Haplomics, Inc. Factor viii mutation repair and tolerance induction
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
EA201890671A1 (ru) 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
CN113831415A (zh) 2013-06-28 2021-12-24 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
BR112016009064A2 (pt) 2013-10-22 2017-09-19 Inst Nat Sante Rech Med Dispositivo de emplastro cutâneo; sistema de liberação de fármaco; kit; e método de tratamento da hemofilia em um indivíduo em necessidade do mesmo
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
BR112016015512B1 (pt) 2014-01-10 2023-12-19 Bioverativ Therapeutics Inc Proteína quimérica, composição farmacêutica e seus usos
US20160347787A1 (en) 2014-02-04 2016-12-01 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CA2940127A1 (en) * 2014-02-19 2015-08-27 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112018009732A8 (pt) 2015-11-13 2019-02-26 Baxalta GmbH ?polinucleotídeo, vetor de vírus adeno-associado, partícula de vírus adeno-associado, célula hospedeira, métodos para produzir uma partícula de vírus adeno-associado, para tratar hemofilia a, para transduzir uma célula hospedeira, e, uso de uma partícula de vírus adeno-associado?
TW202302627A (zh) 2015-11-13 2023-01-16 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
CN109790529A (zh) 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
EP3622065A1 (en) * 2017-05-09 2020-03-18 Emory University Clotting factor variants and their use
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
MX2020008152A (es) 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor viii.
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CA3106590A1 (en) 2018-07-16 2020-01-23 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
KR20220024628A (ko) 2019-06-19 2022-03-03 바이오버라티브 테라퓨틱스 인크. 혈우병 및 낮은 골 무기질 밀도를 치료하기 위한 재조합 인자 viii-fc
WO2020257586A2 (en) 2019-06-20 2020-12-24 Baxalta Incorporated Method of treatment with viral-based gene therapy
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
EP4314819A1 (en) * 2021-03-31 2024-02-07 Haemonetics Corporation Hemostasis measurement device quality control formulations
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2023028456A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
AU5772886A (en) * 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1456235A4 (en) * 2001-11-30 2005-08-17 Univ Emory VARIANTS OF DOMAIN C2 OF FACTOR VIII
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
DE60133541D1 (de) 2008-05-21
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28
PL202936B1 (pl) 2009-08-31
EP1280540A1 (en) 2003-02-05
US7122634B2 (en) 2006-10-17
RS50364B (sr) 2009-11-10
AU3841601A (en) 2001-09-24
HUP0300586A3 (en) 2006-11-28
NL300808I2 (nl) 2020-12-21
BE2016C024I2 (ko) 2020-01-30
HUS1600020I1 (hu) 2016-06-28
CA2400295C (en) 2012-01-10
NO2016007I1 (no) 2016-05-10
ES2304379T3 (es) 2008-10-16
NO331935B1 (no) 2012-05-07
EP1280540B1 (en) 2008-04-09
ME00601B (me) 2011-12-20
BR0109131A (pt) 2004-12-07
SK14392002A3 (sk) 2003-06-03
DK1280540T3 (da) 2008-07-14
ATE391512T1 (de) 2008-04-15
US7012132B2 (en) 2006-03-14
HK1051004A1 (en) 2003-07-18
BR122013026957A2 (ko) 2004-12-07
EE200200510A (et) 2004-02-16
JP2003526358A (ja) 2003-09-09
MXPA02008798A (es) 2003-04-25
US20030068785A1 (en) 2003-04-10
WO2001068109A1 (en) 2001-09-20
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
AU2001238416B2 (en) 2004-09-02
UA75064C2 (en) 2006-03-15
MEP8209A (en) 2011-12-20
JP4044337B2 (ja) 2008-02-06
SK286205B6 (sk) 2008-05-06
BR122013026957A8 (pt) 2017-02-21
CZ298250B6 (cs) 2007-08-01
YU68002A (sh) 2005-11-28
LU93049I2 (fr) 2016-06-27
CY2016011I1 (el) 2016-10-05
CY1108179T1 (el) 2014-02-12
US6458563B1 (en) 2002-10-01
CA2400295A1 (en) 2001-09-20
KR20020081426A (ko) 2002-10-26
SI1280540T1 (sl) 2008-08-31
FR16C0016I1 (ko) 2016-04-29
IL151371A (en) 2010-12-30
CZ20023346A3 (cs) 2003-01-15
DE60133541T2 (de) 2009-05-07
HUP0300586A2 (hu) 2003-06-28
CN1416348A (zh) 2003-05-07
RU2002124123A (ru) 2004-03-27
CY2016011I2 (el) 2016-10-05
NO2016007I2 (no) 2016-05-10
PL359672A1 (en) 2004-09-06
NO20024296L (no) 2002-11-08
BRPI0109131B1 (pt) 2020-08-25
BRPI0109131B8 (pt) 2021-07-06
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
EP1280540A4 (en) 2004-11-03
CN1191360C (zh) 2005-03-02
FR16C0016I2 (fr) 2018-11-02
KR100485525B1 (ko) 2005-04-28
NZ520799A (en) 2004-06-25
PT1280540E (pt) 2008-06-09
NL300808I1 (ko) 2016-05-18
LTC1280540I2 (lt) 2020-05-25

Similar Documents

Publication Publication Date Title
IL151371A (en) Modified porcine factor viii and pharmaceutical compositions containing the same
HK1043543A1 (en) Modified factor VIII.
ATE289332T1 (de) Silikongel enthaltend salizylsäure
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
ATE169317T1 (de) Pyridobismidazole enthaltendes rigid-rod-polymer
ES2176600T3 (es) Derivado de la propiofenona y procedimientos para su preparacion.
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
ATE171873T1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
EA200100674A1 (ru) Клатраты дегидроэпиандростерона и соответствующие фармацевтические композиции
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.